Lysine

Lysine

SCHEMBL7573653

NC(=O)/C=C/C(N)=O.NCCCC[C@H](N)C(=O)O

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.77
ARG2 P78540 4/20 0.48
ARG1 P05089 3/20 0.48
NOS2 P35228 6/20 0.47
NOS1 P29475 4/20 0.47
NOS3 P29474 3/20 0.47
CYP1A2 P05177 2/20 0.47
TSHR P16473 2/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 2/20 0.47
GLA P06280 1/20 0.47
NFKB1 P19838 1/20 0.47
APEX1 P27695 1/20 0.47
RNPEP Q9H4A4 1/20 0.47
BLM P54132 2/20 0.46
KMT2A Q03164 2/20 0.45
ALOX15 P16050 1/20 0.45
PMP22 Q01453 1/20 0.45
DDAH1 O94760 1/20 0.45
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lysine SCHEMBL31644218 0.88 GSR (0.91) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL1042282 0.88 GSR (0.91) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL31039861 0.88 GSR (0.91) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL4641859 0.88 GSR (0.91) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL5060018 0.88 GSR (0.91) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL15286920 0.88 GSR (0.91) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL12867528 0.88 GSR (1.00) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL1645 0.88 GSR (1.00) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL7343 0.88 GSR (1.00) GSRARG2ARG1NOS2NOS1
Lysine SCHEMBL9439278 0.88 GSR (1.00) GSRARG2ARG1NOS2NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0749452-B1 POLYMER-CONJUGATED MALONIC ACID DERIVATIVES AND THEIR USE AS MEDICAMENTS AND DIAGNOSTIC AGENTS GLYCOREX AB (SE) 2002-07-17 EP claimed
US-6037467-A Methods for preparing carbohydrate-containing hydrophilic polymers GLYCOREX AB (SE) 2000-03-14 US claimed
US-5817742-A Polymer-conjugated malonic acid derivatives and their use as medicaments and diagnostic agents HOECHST AKTIENGESELLSCHAFT (DE) 1998-10-06 US claimed
US-9719987-B2 Immunoadsorbent compositions comprising hyaluronic acid oligosaccharides FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL) (ES) 2017-08-01 US disclosed
US-20150192576-A1 METHODS AND REAGENTS FOR PREVENTION AND/OR TREATMENT OF TRANSPLANT REJECTION FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL) (ES) 2015-07-09 US disclosed
EP-2698636-A1 Methods and reagents for prevention and/or treatment of transplant rejection Fundació Institut d'Investigació Biomèdica de Bellvitge (ES) 2014-02-19 EP disclosed
US-6406894-B1 BIODEGRADABLE POLYMER, DISACCHARIDE OR OLIGOSACCHARIDE, CROSSLINKING AND COUPLING GLYCOREX AB (SE) 2002-06-18 US disclosed
US-6037467-A Methods for preparing carbohydrate-containing hydrophilic polymers GLYCOREX AB (SE) 2000-03-14 US disclosed
US-5817742-A Polymer-conjugated malonic acid derivatives and their use as medicaments and diagnostic agents HOECHST AKTIENGESELLSCHAFT (DE) 1998-10-06 US disclosed
US-5470843-A Carbohydrate-containing polymers, their preparation and use HOECHST AKTIENGESELLSCHAFT (DE) 1995-11-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150192576-A1 METHODS AND REAGENTS FOR PREVENTION AND/OR TREATMENT OF TRANSPLANT REJECTION CD44, HLA-C, HAVCR2 GSR 1877/4885ARG2 2975/4885ARG1 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.